Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    SAGE Publications ; 2019
    In:  Sports Health: A Multidisciplinary Approach Vol. 11, No. 4 ( 2019-07), p. 355-366
    In: Sports Health: A Multidisciplinary Approach, SAGE Publications, Vol. 11, No. 4 ( 2019-07), p. 355-366
    Abstract: Amid extensive debate, evidence surrounding the use of platelet-rich plasma (PRP) for musculoskeletal injuries has rapidly proliferated, and an overall assessment of efficacy of PRP across orthopaedic indications is required. Objectives: (1) Does PRP improve patient-reported pain in musculoskeletal conditions? and (2) Do PRP characteristics influence its treatment effect? Data Sources: MEDLINE, EMBASE, Cochrane, CINAHL, SPORTDiscus, and Web of Science libraries were searched through February 8, 2017. Additional studies were identified from reviews, trial registries, and recent conferences. Study Selection: All English-language randomized trials comparing platelet-rich therapy with a control in patients 18 years or older with musculoskeletal bone, cartilage, or soft tissue injuries treated either conservatively or surgically were included. Substudies of previously reported trials or abstracts and conference proceedings that lacked sufficient information to generate estimates of effect for the primary outcome were excluded. Study Design: Systematic review and meta-analysis. Level of Evidence: Level 1. Data Extraction: All data were reviewed and extracted independently by 3 reviewers. Agreement was high between reviewers with regard to included studies. Results: A total of 78 randomized controlled trials (5308 patients) were included. A standardized mean difference (SMD) of 0.5 was established as the minimum for a clinically significant reduction in pain. A reduction in pain was associated with PRP at 3 months (SMD, –0.34; 95% CI, –0.48 to –0.20) and sustained until 1 year (SMD, –0.60; 95% CI, –0.81 to –0.39). Low- to moderate-quality evidence supports a reduction in pain for lateral epicondylitis (SMD, –0.69; 95% CI, –1.15 to –0.23) and knee osteoarthritis (SMD, –0.91; 95% CI, –1.41 to –0.41) at 1 year. PRP characteristics did not influence results. Conclusion: PRP leads to a reduction in pain; however, evidence for clinically significant efficacy is limited. Available evidence supports the use of PRP in the management of lateral epicondylitis as well as knee osteoarthritis.
    Type of Medium: Online Resource
    ISSN: 1941-7381 , 1941-0921
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2019
    detail.hit.zdb_id: 2474978-3
    SSG: 31
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages